CliffBio
small molecule

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameEPIRUBICIN HYDROCHLORIDE
Active ingredientEPIRUBICIN HYDROCHLORIDE
Strength200MG/100ML (2MG/ML)
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalOctober 2007
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

EPIRUBICIN HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio